Skip to main content
EJNMMI Research
Fig. 4 | EJNMMI Research

Fig. 4

From: Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumab

Fig. 4

Comparison of the distribution of VEGF, bevacizumab, and 111In in FaDu xenograft sections. The rows are examples of two sections from different FaDu xenografts injected with 111In-bevacizumab and an excess of unlabelled bevacizumab at 5 days. The left panels (green) are immunofluorescence images of VEGF staining, the centre panels (red) are immunofluorescence images of bevacizumab staining, and the right panels (grayscale) are autoradiographs of 111In distribution

Back to article page